PMID(sorted ascending)
clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in peru.treatment for cutaneous leishmaniasis (cl) with standard pentavalent antimonial therapy is hampered by cumbersome administration, toxicity, and potential failure. knowledge of factors influencing treatment outcome is essential for successful management.200818171254
a battery of 12 microsatellite markers for genetic analysis of the leishmania (viannia) guyanensis complex.we used 12 microsatellite markers developed for leishmania braziliensis to genotype 28 strains of the main species of the leishmania guyanensis complex (i.e. l. guyanensis and l. panamensis) collected in ecuador and peru. the important heterozygote deficits observed in these populations are similar with the previous data obtained in l. braziliensis and raise again the debate on the reproductive mode of these protozoan parasites. the data showed genetic polymorphism and geographical differentiati ...201020609264
association of the endobiont double-stranded rna virus lrv1 with treatment failure for human leishmaniasis caused by leishmania braziliensis in peru and bolivia.cutaneous and mucosal leishmaniasis, caused in south america by leishmania braziliensis, is difficult to cure by chemotherapy (primarily pentavalent antimonials [sb(v)]). treatment failure does not correlate well with resistance in vitro, and the factors responsible for treatment failure in patients are not well understood. many isolates of l. braziliensis (>25%) contain a double-stranded rna virus named leishmaniavirus 1 (lrv1), which has also been reported in leishmania guyanensis, for which a ...201626123565
Displaying items 1 - 3 of 3